Ignite Creation Date:
2024-05-05 @ 11:53 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01442792
Status:
COMPLETED
Last Update Posted:
2022-06-23
First Post:
2011-08-18
Brief Title:
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Prospective Multi-center Randomized Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban a Direct Factor Xa Inhibitor on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
X-PLORER
Brief Summary:
Balloon angioplasty Percutaneous Coronary Intervention PCI is commonly used to treat patients with obstructive coronary artery disease CAD Although PCI is highly effective for the management of CAD it can potentiate an existing prothrombotic state around lesion areas A certain level of anticoagulation is required to perform planned PCI safely and to minimize the periprocedural risk of thrombosis and its attendant complications including myocardial ischemia and infarction heart attack Many different anti-thrombotic regimens have been investigated and are currently in use The aim of this study is to explore whether Rivaroxaban as compared to unfractionated heparin on the background of standard dual antiplatelet therapy can effectively suppress thrombosis and related adverse ischemic events upon balloon inflation and stent expansion during elective PCI without increasing bleeding The treatment assignment will be done in a semi-blinded design eg no blinding for randomization either to Rivaroxaban one of the three arms or the control UFH group However all will be blinded for the treatment dose of rivaroxaban either 10mg or 20 mgThe 10 mg rivaroxaban plus 50 IU UFH arm will not be blinded
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-001094-58 | EUDRACT_NUMBER | None | None |